Some people use Zollinger-Ellison syndrome and gastrinoma interchangeably. Learn the similarities and differences between the ...

Tragically, it claims the lives of 9,558 people annually, with over 70% succumbing within a year of being diagnosed. Just one ...

Patients with cancer that has spread from other organs to the liver (colorectal, breast, neuroendocrine, sarcomas and others) are evaluated by a multidisciplinary team including an experienced liver ...

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients with gastroenteropancreatic neuroendocrine tumors, a phase 3 trial found.

According to national cancer institute ... s ordeal began with a small, 2 cm neuroendocrine tumour in the rectum, which eventually spread to the liver, forming three additional tumours.

“These medicines will give people more treatment options and help them to live well for longer,” says Pharmac’s Director Equity and Engagement, Dr Nicola Ngawati. “We expect about 180 people will ...

Identical to MIB1. ‡ Gastrointestinal neuroendocrine tumor. § Pancreatic neuroendocrine tumor. NET: Neuroendocrine tumor. Data from [20,94]. T1 Tumor limited to the pancreas and size <2 cm T2 ...

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...